Literature DB >> 10483780

Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo.

M H Deininger1, M Weller, J Streffer, M Mittelbronn, R Meyermann.   

Abstract

Cyclooxygenases (COX, prostaglandin endoperoxide synthases, PGG/H synthases) are potent mediators of inflammation. While COX-1 is constitutively expressed in a wide range of tissues, COX-2 is cytokine inducible. Although COX-1 expression is observed in normal tissue, enhanced COX-2 expression has been attributed a key role in the development of edema, impeding blood flow and immunomodulation observed in pathologically altered tissues. Here, we have analyzed the expression of COX-1 and COX-2 in 50 gliomas and 10 control brains with no neuropathological alterations by immunohistochemistry; 22 glioblastoma multiforme, 9 anaplastic astrocytomas, 5 protoplasmic astrocytomas, 1 gemistocytic astrocytoma and 13 fibrillary astrocytomas were included in the study. Compared with control brains, accumulation of COX-1 was detected in 20-50% of all cells in both low- and high-grade gliomas. Double-labeling experiments revealed COX-1 expression in subsets of macrophages/microglial cells within the tumor parenchyma and in areas of infiltrative tumor growth. Of the COX-1-positive cells, 90% expressed MHC class II antigens. No COX-1 immunoreactivity was observed in tumor cells. COX-2-positive cells accumulated in tumor cells and in single macrophages/microglial cells in the immediate vicinity of necroses. Further studies are required to determine whether COX-2 is involved in the development of necrosis or, more likely, whether COX-2 is a part of the tumor tissue response to necrosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10483780     DOI: 10.1007/s004010051075

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  24 in total

1.  Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme.

Authors:  V A Levin; P Giglio; V K Puduvalli; J Jochec; M D Groves; W K A Yung; K Hess
Journal:  J Neurooncol       Date:  2005-11-29       Impact factor: 4.130

Review 2.  Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.

Authors:  Onder Onguru; Mary B Casey; Sabine Kajita; Nobuki Nakamura; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 3.  Targets for therapy in ependymoma.

Authors:  Nicole A Shonka
Journal:  Target Oncol       Date:  2011-03-29       Impact factor: 4.493

4.  Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme.

Authors:  Peter Sminia; T Rianne Stoter; Paul van der Valk; Paula H M Elkhuizen; Thea M Tadema; Gitta K Kuipers; W Peter Vandertop; M Vincent M Lafleur; Ben J Slotman
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

Review 5.  Cyclooxygenase-2 in glioblastoma multiforme.

Authors:  Jiange Qiu; Zhi Shi; Jianxiong Jiang
Journal:  Drug Discov Today       Date:  2016-09-28       Impact factor: 7.851

6.  Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma.

Authors:  S G Temel; Z Kahveci
Journal:  J Mol Histol       Date:  2010-01-06       Impact factor: 2.611

7.  The lectin concanavalin-A signals MT1-MMP catalytic independent induction of COX-2 through an IKKgamma/NF-kappaB-dependent pathway.

Authors:  Asmaa Sina; Sébastien Proulx-Bonneau; Alain Roy; Laurent Poliquin; Jian Cao; Borhane Annabi
Journal:  J Cell Commun Signal       Date:  2010-01-27       Impact factor: 5.782

8.  Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

Authors:  Santosh Kesari; David Schiff; Lisa Doherty; Debra C Gigas; Tracy T Batchelor; Alona Muzikansky; Alison O'Neill; Jan Drappatz; Alice S Chen-Plotkin; Naren Ramakrishna; Stephanie E Weiss; Brenda Levy; Joanna Bradshaw; Jean Kracher; Andrea Laforme; Peter McL Black; Judah Folkman; Mark Kieran; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2007-04-23       Impact factor: 12.300

Review 9.  iNOS: a potential therapeutic target for malignant glioma.

Authors:  A Jahani-Asl; A Bonni
Journal:  Curr Mol Med       Date:  2013-09       Impact factor: 2.222

10.  Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy.

Authors:  Khong Bee Kang; Congju Zhu; Sook Kwin Yong; Qiuhan Gao; Meng Cheong Wong
Journal:  Mol Cancer       Date:  2009-08-25       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.